7 active not recruiting, 6 unknown, 2 completed, 2 recruiting. 13 Phase 2, 9 Phase 1, 2 Phase 3.
Follow Biotheus Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Biotheus Inc. | 100 | 2025-08-19 | 2026-07-23 |
| A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC PM8002, PM1009, atezolizumab - HCC, Liver Cancer | Phase 1 / Phase 2 | Not yet recruiting | Biotheus Inc. | 140 | 2024-12-01 | 2024-12-16 |
| PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer PM8002, Paclitaxel, Topotecan - SCLC | Phase 3 | Active not recruiting | Biotheus Inc. | 404 | 2024-11-13 | 2026-10-22 |
| PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC PM8002, Nab-Paclitaxel, Placebo - Triple Negative Breast Cancer(TNBC) | Phase 3 | Active not recruiting | Biotheus Inc. | 392 | 2024-06-11 | 2026-07-29 |
| A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours PM1021, PM8001 - Advanced Solid Tumours | Phase 1 | Unknown | Biotheus Inc. | 30 | 2023-10-30 | 2023-02-08 |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC PM8002, Carboplatin, Pemetrexed - NSCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 64 | 2023-06-26 | 2025-04-03 |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC PM8002, Platinum, Etoposide - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 50 | 2023-06-01 | 2025-03-12 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With NEN PM8002, FOLFIRI - Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | Biotheus Inc. | 31 | 2023-05-17 | 2026-07-09 |
| A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours PM1009 injection - Advanced Tumor | Phase 1 | Unknown | Biotheus Inc. | 54 | 2022-11-21 | 2023-02-08 |
| A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM PM8002, Pemetrexed, Cisplatin - MPM | Phase 2 | Completed | Biotheus Inc. | 31 | 2022-08-13 | 2026-06-08 |
| Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors PM1032 injection - Advanced Tumor | Phase 1 / Phase 2 | Unknown | Biotheus Inc. | 200 | 2022-07-08 | 2023-05-06 |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC PM8002, nab-paclitaxel - TNBC | Phase 1 / Phase 2 | Active not recruiting | Biotheus Inc. | 42 | 2022-07-01 | 2025-03-11 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC PM8002, Paclitaxel - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 99 | 2022-05-27 | 2024-12-18 |
| A Study of PM1015 in Patients With Advanced Solid Tumors CD73 Antigen - Advanced Solid Tumor | Phase 1 | Unknown | Biotheus Inc. | 20 | 2022-05-10 | 2023-07-18 |
| PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma PM8002, FOLFOX regimen - Hepatocellular Carcinoma | Phase 2 | Completed | Biotheus Inc. | 35 | 2022-04-22 | 2026-07-09 |
| A Study of PM1022 in Patients With Advanced Tumors PM1022 - Advanced Tumors | Phase 1 / Phase 2 | Unknown | Biotheus Inc. | 200 | 2022-04-11 | 2023-05-22 |
| Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors PM1003 Injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Unknown | Biotheus Inc. | 285 | 2021-09-07 | 2023-05-17 |
| PM8002 in the Treatment of Patients With Advanced Solid Tumors PM8002 - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Biotheus Inc. | 380 | 2021-03-09 | 2024-12-05 |
Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Liver Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Triple Negative Breast Neoplasms (1)
130-nm albumin-bound paclitaxel (2) · Carboplatin (2) · Paclitaxel (2) · Pemetrexed (2) · 5'-Nucleotidase (1) · Bevacizumab (1) · Cisplatin (1) · Etoposide (1) · Folfox protocol (1) · IFL protocol (1) · Platinum (1) · Topotecan (1) · atezolizumab (1)
China (16)
Ye Guo (5) · Haifeng Liu (2) · Ying Cheng (2) · Caicun Zhou (1) · Jia Fan (1) · Jian Zhang, professor (1) · Jianming Xu (1) · Jieer Ying (1) · Jiong Wu, professor (1) · Lin Shen, PhD (1) · Ruihua Xu, PhD, MD (1) · Vineet Kwatra (1) · Wu Jiong (1) · Wu Yilong, PhD (1)